Patient characteristics and treatments received by TET2 mutational status
| . | N (%) . | TET-WT . | TET2-mut . | P value* . |
|---|---|---|---|---|
| N | 213 | 155 | 58 | |
| Treatments received | ||||
| AZA alone | 42 (20) | 30 (19) | 12 (21) | .60 |
| DEC alone | 144 (68) | 103 (66) | 41 (71) | |
| DEC + other | 27 (13) | 22 (14) | 5 (9) | |
| Age, ≥70 y | 103 (48) | 72 (46) | 31 (53) | .44 |
| Sex | ||||
| Male | 155 (73) | 118 (76) | 37 (64) | .085 |
| Female | 58 (27) | 37 (24) | 21 (36) | |
| FAB | ||||
| RA | 30 (14) | 19 (12) | 11 (19) | .13 |
| RARS | 24 (11) | 15 (10) | 9 (16) | |
| RAEB | 125 (59) | 97 (63) | 28 (48) | |
| RAEB-t | 6 (3) | 4 (3) | 2 (3) | |
| CMML | 21 (10) | 13 (8) | 8 (14) | |
| Other | 7 (3) | 7 (5) | 0 (0) | |
| IPSS risk group | ||||
| Low | 11 (5) | 5 (3) | 6 (10) | .019 |
| Int-1 | 86 (40) | 56 (36) | 30 (52) | |
| Int-2 | 76 (36) | 61 (39) | 15 (26) | |
| High | 37 (17) | 31 (20) | 6 (10) | |
| Unknown | 3 (1) | 2 (1) | 1 (2) | |
| Cytogenetics | ||||
| Normal or –Y alone | 107 (50) | 68 (44) | 39 (67) | .022 |
| Complex | 51 (24) | 45 (29) | 6 (10) | |
| −7/7q- isolated or +1 | 14 (7) | 12 (8) | 2 (3) | |
| +8 isolated | 11 (5) | 8 (5) | 3 (5) | |
| 20q- isolated | 7 (3) | 6 (4) | 1 (2) | |
| 5q- isolated or +1 | 3 (1) | 3 (2) | 0 (0) | |
| Other | 13 (6) | 9 (6) | 4 (7) | |
| Unknown | 7 (3) | 4 (3) | 3 (5) |
| . | N (%) . | TET-WT . | TET2-mut . | P value* . |
|---|---|---|---|---|
| N | 213 | 155 | 58 | |
| Treatments received | ||||
| AZA alone | 42 (20) | 30 (19) | 12 (21) | .60 |
| DEC alone | 144 (68) | 103 (66) | 41 (71) | |
| DEC + other | 27 (13) | 22 (14) | 5 (9) | |
| Age, ≥70 y | 103 (48) | 72 (46) | 31 (53) | .44 |
| Sex | ||||
| Male | 155 (73) | 118 (76) | 37 (64) | .085 |
| Female | 58 (27) | 37 (24) | 21 (36) | |
| FAB | ||||
| RA | 30 (14) | 19 (12) | 11 (19) | .13 |
| RARS | 24 (11) | 15 (10) | 9 (16) | |
| RAEB | 125 (59) | 97 (63) | 28 (48) | |
| RAEB-t | 6 (3) | 4 (3) | 2 (3) | |
| CMML | 21 (10) | 13 (8) | 8 (14) | |
| Other | 7 (3) | 7 (5) | 0 (0) | |
| IPSS risk group | ||||
| Low | 11 (5) | 5 (3) | 6 (10) | .019 |
| Int-1 | 86 (40) | 56 (36) | 30 (52) | |
| Int-2 | 76 (36) | 61 (39) | 15 (26) | |
| High | 37 (17) | 31 (20) | 6 (10) | |
| Unknown | 3 (1) | 2 (1) | 1 (2) | |
| Cytogenetics | ||||
| Normal or –Y alone | 107 (50) | 68 (44) | 39 (67) | .022 |
| Complex | 51 (24) | 45 (29) | 6 (10) | |
| −7/7q- isolated or +1 | 14 (7) | 12 (8) | 2 (3) | |
| +8 isolated | 11 (5) | 8 (5) | 3 (5) | |
| 20q- isolated | 7 (3) | 6 (4) | 1 (2) | |
| 5q- isolated or +1 | 3 (1) | 3 (2) | 0 (0) | |
| Other | 13 (6) | 9 (6) | 4 (7) | |
| Unknown | 7 (3) | 4 (3) | 3 (5) |
Test includes only known categories, χ2 test used for cytogenetics.